SignalXSignalX

EWTX Edgewise Therapeutics, Inc.

Q3 2025 10-Q
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Edgewise Therapeutics, Inc. Overview

Edgewise Therapeutics, Inc. (EWTX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New risk: Initiated Phase 1 trial for EDG-15400 in Sept 2025, expanding clinical development pipeline
  • • Material update: Net loss $117.6M YTD Sept 2025, accumulated deficit $496.2M, reflecting increased R&D and operational expenses
+3 more insights

Quarterly Financial Summary
XBRL

Net Income

-$41M

ROE

-7.3%

Total Assets

$583M

Source: XBRL data from Edgewise Therapeutics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Edgewise Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.